Introducing AGS' Microalgae Extracellular Vesicles as a universal delivery system to specific brain neurons.
When nasally administered, these loaded MEVs can carry a diversity of innovative biologics - such as RNA, DNA, proteins and peptides - through the olfactory neuronal networks to specific regions of the brain.
From the olfactory neurons, MEVs move to the olfactory bulb, and from there, they travel by axon transport and trans-synaptic transport, throughout the entire olfactory pathway to reach targeted regions of the brain that are in direct and indirect connection to the olfactory tract, where they may deliver their therapeutic payload for proper expression.
This promising new way to deliver therapies to the brain is targeted, non-invasive and avoids the blood brain barrier, opening a new door to treat many serious brain disorders including : depression, post traumatic stress disorders, Alzheimer’s and Parkinson’s diseases, Rett Syndrome, dementia, and disorders that require the therapeutic agent to be delivered inside neurons.
The ability of AGS MEVs to deliver innovative medicines to the brain may offer the best hope of ushering in a new era of treatment for patients with brain diseases.
Related Publications :
| Intranasal Use of Innovative Therapeutics Bypasses the Blood Brain Barrier and with an Effective Delivery System Could be a Promising New Approach to Treating Brain Diseases |